Simplifying procedure for prediction of resistance risk in CML patients — Test of sensitivity to TKI ex vivo-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Simplifying procedure for prediction of resistance risk in CML patients — Test of sensitivity to TKI ex vivo

Published:2016-05 Issue: Volume:58 Page:67-75
ISSN:1079-9796
Container-title:Blood Cells, Molecules, and Diseases
language:en
Short-container-title:Blood Cells, Molecules, and Diseases

Author:

Žáčková Markéta,Macháčková-Lopotová Tereza,Ondráčková Zuzana,Kuželová Kateřina,Klamová Hana,Moravcová Jana

Funder

Ministry of Health of the Czech Republic

Publisher

Elsevier BV

Subject

Cell Biology,Hematology,Molecular Biology,Molecular Medicine

Reference59 articles.

1. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;N. Engl. J. Med.,2010

2. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy;Shami;Leukemia,2012

3. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

4. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BRC-ABL mutation really matter?;Branford;Blood,2009

5. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia;White;J. Clin. Oncol.,2007

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells;PLOS ONE;2023-05-04

2. Inhibition of Casein Kinase 2 induces Cell Death in Chronic Myelogenous Leukemia Cells with Different Mechanisms of Resistance to Tyrosine Kinase Inhibitors;2021-06-28

3. Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines;LEUKEMIA RES;2017

4. Imatinib reduces proliferation of leukemic cells in vitro;Bangladesh Journal of Medical Science;2017-03-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3